Applied Evidence

What we know—and don’t—about non-nutritive sweeteners

Author and Disclosure Information

 

References

Other lines of investigation, including animal studies, have shown that long-term use of NNSs is associated with numerous metabolic derangements including weight gain.21 The negative effects of NNSs appear to be the greatest in males and those who are obese and have high-calorie diets.21

A 2017 meta-analysis concluded that evidence from RCTs does not support a benefit of NNSs on weight management, and that routine consumption of NNSs may be associated with increased body mass index (BMI) and cardiometabolic risk.22 Another systematic review and meta-analysis found that there was a higher pooled risk for obesity among those who drank beverages containing NNSs vs those who drank sugar-containing beverages.23

Based on the most current literature, we conclude that NNSs are not beneficial for weight loss. While there is concern about weight gain through psychological effects (stimulation of sweetness receptors without satiety), further well-designed research is needed to explore whether this concern has merit.

WHAT IS THE EFFECT OF NNSs ON APPETITE?

There appears to be no effect. While original studies seemed to indicate there was an effect, later studies leaned to the contrary.

Consumption of diet beverages or non- nutritive sweeteners increases with age and is especially common among women with higher levels of education and income.

The notion that NNSs might enhance appetite and food intake was advanced in the 1980s by John Blundell and his research team.24 The hypothesis was that since NNSs uncouple sweet taste and calories, they do not exert the normal post-ingestive inhibitory influence that real sugar does. This, in turn, disrupts appetite control mechanisms.25-27

Continue to: However, subsequent research studies...

Pages

Recommended Reading

The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
MDedge Family Medicine
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adults
MDedge Family Medicine
CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes
MDedge Family Medicine
FDA declines dapagliflozin indication as adjunct for type 1 diabetes
MDedge Family Medicine
Plant-based foods could keep type 2 diabetes at bay
MDedge Family Medicine
DECLARE-TIMI58 shows improved kidney function with dapagliflozin
MDedge Family Medicine
Inadequate glycemic control in type 1 diabetes leads to increased fracture risk
MDedge Family Medicine
No increase in UTI risk with SGLT-2 inhibitors
MDedge Family Medicine
Endocrine Society advises on diabetes care for older adults
MDedge Family Medicine
GLP-1 agonists, SGLT2 inhibitors offer more options in diabetes management
MDedge Family Medicine